The Trump administration is preparing a stopgap measure that could allow certain previously restricted peptides to be sold temporarily while federal health officials write new regulations, according to a Washington Post report.
The plan, described by two people familiar with the matter, would let some compounding pharmacies dispense peptides marketed as medical treatments and wellness products even though safety and efficacy claims have not been fully tested. The timing remains unclear, and the policy could still change. It is not known which specific peptides would be included.
If implemented, interim enforcement discretion would create a legal pathway for compounding pharmacies to produce peptide treatments outside current FDA restrictions — a shift that could reshape the business models of telehealth peptide platforms and raise consumer-safety questions.
What happened
According to the Washington Post, reported via Becker’s Hospital Review, the Department of Health and Human Services is preparing guidance that would allow certain previously restricted peptide compounds to be sold on a temporary basis while new federal rules are drafted.
The proposal is not final. Two people familiar with the matter told the Post that the plan would permit some compounding pharmacies to dispense peptides marketed as medical treatments and wellness products, despite the absence of full safety and efficacy testing.
Federal officials are reportedly seeking guardrails as part of any interim arrangement, including enhanced patient disclosures and adverse event reporting. Which specific peptides would be covered — and when any guidance might take effect — remains unknown. The policy could still change before it is issued.
Why it matters
Peptide compounding has operated in a regulatory gray zone, with FDA enforcement actions restricting certain unapproved products. Interim enforcement discretion could give 503A compounding pharmacies a temporary legal footing to produce and dispense peptide treatments that federal regulators have previously challenged.
For telehealth peptide platforms, a shift in enforcement could affect how they market, prescribe, and fulfill orders. For consumers, the change could mean broader access to compounds that have not completed full safety and efficacy evaluation under the FDA approval process.
The reported focus on guardrails — such as patient disclosures and adverse event reporting — suggests federal officials are weighing access against oversight, though the details and effectiveness of any such measures remain unclear.
What to watch next
- Whether HHS formally issues interim enforcement discretion guidance, and in what form.
- Which specific peptide compounds, if any, would be included.
- How FDA officials respond to any new enforcement posture.
- Whether guardrails such as patient disclosures and adverse event reporting are defined and enforced.
- How telehealth platforms and 503A compounding pharmacies adjust their operations.
Sources
Washington Post (via Becker’s Hospital Review)
Industry information only. Not medical or legal advice.
